Eysuvis Suspension/ Drops
Product Images NDC 71571-333

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Eysuvis (NDC 71571-333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.4 mL Bottle (Contain 2 4ml)

Label for Eysuvis (loteprednol etabonate) ophthalmic suspension 0.25%, sterile, in a 2.4 mL volume. The label states it is for topical application in the eye and directs to see the package insert for dosage. Manufactured for Kala Pharmaceuticals, Inc., Watertown, MA. Marked as Rx only and includes an NDC number 71571-333-24 and a sample designation.*

FDA Label Image

2.4 mL Carton (Carton 2 4ml)

Packaging label for Eysuvis (loteprednol etabonate) ophthalmic suspension 0.25%, 2.4 mL sterile drops. The label includes dosage instructions to shake for 2 to 3 seconds and storage guidance at 15°C to 25°C. It notes the product is Rx only, for topical eye application, and is a professional sample not for retail sale. Manufactured for Kala Pharmaceuticals, Watertown, MA.*

FDA Label Image

Bottle Label (Final Container)

Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, 1 mL vial label. The label indicates the product is sterile and for topical application in the eye. It shows the NDC 71571-333-01 and features sample marking, lot number, and expiration date space. Manufactured by Alcon Laboratories, Inc., Fort Worth, TX.*

FDA Label Image

Carton Label (Final Carton Label)

Eysuvis (loteprednol etabonate) ophthalmic suspension 0.25%, 1 mL sterile drops packaging label by Alcon Laboratories, Inc. The label includes dosing instructions to shake for 2 to 3 seconds, storage conditions to keep upright at 15°C to 25°C, and warnings not to freeze or use if tamper-evident overcap is not intact. It is marked as a professional sample, not for retail sale, and intended for topical application in the eye.*

FDA Label Image

Bottle 8.3ml (Bottle 8.3 mL)

Label for Eysuvis (loteprednol etabonate) ophthalmic suspension 0.25%, 8.3 mL, a sterile eye drop solution. The label indicates the product is Rx only, for topical application in the eye, and manufactured by Alcon Laboratories, Inc., Fort Worth, TX. The NDC number 71571-333-83 is shown along with a QR code and barcode.*

FDA Label Image

Carton 8.3ml (Carton 8.3ml)

The packaging label for Eysuvis 0.25% (loteprednol etabonate ophthalmic suspension) contains 8.3 mL of sterile solution for topical eye application. It is produced by Alcon Laboratories, Inc. The label includes active ingredient strength of 2.5 mg/mL, storage instructions to keep upright at 15°C to 25°C and shake for 2 to 3 seconds before use, and tamper-evident warnings. The label also lists inactive ingredients and preservative benzalkonium chloride 0.01%.*

FDA Label Image

Chemical Structure (Eysuvis 01)

Chemical structure of loteprednol etabonate, the active ingredient in Eysuvis ophthalmic suspension 2.5 mg/mL by Alcon Laboratories, Inc.*

FDA Label Image

Figure 1 (Eysuvis 02)

Four forest plot charts from clinical studies comparing the effect of Eysuvis (loteprednol etabonate 2.5 mg/mL ophthalmic suspension) versus vehicle control. Each chart presents mean differences with 95% confidence intervals at Baseline, Day 8, and Day 15 visits, indicating results favoring Eysuvis. Study sample sizes range from 73 to 459 subjects per group.*

FDA Label Image

Figure 2 (Eysuvis 03)

A forest plot showing results from four clinical studies comparing Eysuvis (loteprednol etabonate) ophthalmic suspension against vehicle. Each study displays baseline and Day 15 mean values with standard deviations, plus the difference in means with 95% confidence intervals. All studies indicate a statistically significant difference favoring Eysuvis at Day 15 compared to vehicle.*

FDA Label Image

Figure A (Eysuvis 04)

An instructional illustration showing three steps for handling the Eysuvis ophthalmic suspension bottle. The first step shows the bottle upright with the cap on. The second step illustrates unscrewing or twisting off the cap. The third step depicts discarding the cap into a trash bin.*

FDA Label Image

Figure B (Eysuvis 05)

Eysuvis 2.5 mg/mL ophthalmic suspension in a white plastic bottle with a pink cap. The label shows the proprietary name Eysuvis and generic name loteprednol etabonate. The bottle design appears compact and is meant for prescription eye drop use. Labeling includes dosage form and route of administration.*

FDA Label Image

Figure C (Eysuvis 06)

Eysuvis 2.5 mg/mL ophthalmic suspension bottle by Alcon Laboratories, Inc. The image shows a white plastic dropper bottle with a pink cap, used for eye drop administration. The label includes the brand name and basic product information.*

FDA Label Image

Figure D (Eysuvis 07)

Eysuvis ophthalmic suspension bottle, labeled with loteprednol etabonate 2.5 mg/mL. The image shows a white plastic eye-drop bottle dispensing a drop, manufactured by Alcon Laboratories, Inc.*

FDA Label Image

Figure E (Eysuvis 08)

An instructional illustration showing a person administering ophthalmic drops to the eye. The image depicts a hand holding a dropper bottle above the eye, with drops being applied to the lower eyelid while the eye looks upward.*

FDA Label Image

Figure F (Eysuvis 09)

An instructional diagram showing two images of an Eysuvis ophthalmic suspension bottle with a safety cap. The left image demonstrates a twisting motion to remove the cap, and the right image shows the bottle with the cap removed, illustrating the proper way to open the bottle.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.